Loading...
XSHG
603707
Market cap2.47bUSD
Jul 14, Last price  
10.95CNY
1D
-0.09%
1Q
-4.62%
IPO
24.72%
Name

Nanjing King-friend Biochemical Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
P/S
4.50
EPS
Div Yield, %
0.91%
Shrs. gr., 5y
5.36%
Rev. gr., 5y
18.25%
Revenues
3.93b
+5.89%
499,817,300416,121,068468,728,013581,913,0371,112,726,0031,700,330,6672,469,669,3052,914,880,9303,686,692,9513,712,720,4553,931,387,279
Net income
-189m
L
70,316,20050,490,00587,553,459257,239,597314,222,399424,549,136604,961,604806,122,1851,059,293,3311,090,833,203-189,445,790
CFO
1.62b
+171.93%
193,913,400178,740,925137,280,5650062,368,49300683,631,820595,445,6731,619,167,843
Dividend
Jul 08, 20240.1 CNY/sh

Profile

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd manufactures and sells heparin sodium and low molecular weight heparin products for pharmaceutical companies in the People's Republic of China. It offers enoxaparin sodium, dalteparin sodium, and naqu heparin calcium injections. The company also exports its products primarily to the European and American countries. The company was founded in 2000 and is based in Nanjing, the People's Republic of China.
IPO date
Jul 19, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,931,387
5.89%
3,712,720
0.71%
Cost of revenue
2,865,976
2,546,496
Unusual Expense (Income)
NOPBT
1,065,412
1,166,225
NOPBT Margin
27.10%
31.41%
Operating Taxes
(105,312)
98,850
Tax Rate
8.48%
NOPAT
1,170,723
1,067,375
Net income
(189,446)
-117.37%
1,090,833
2.98%
Dividends
(248,469)
(186,586)
Dividend yield
1.05%
0.64%
Proceeds from repurchase of equity
(5,722)
BB yield
0.02%
Debt
Debt current
1,566,802
1,957,288
Long-term debt
532,663
1,023,075
Deferred revenue
84,987
Other long-term liabilities
82,738
6,170
Net debt
135,192
1,530,249
Cash flow
Cash from operating activities
1,619,168
595,446
CAPEX
(419,068)
Cash from investing activities
(1,176,382)
Cash from financing activities
51,200
FCF
3,399,723
(144,004)
Balance
Cash
1,891,797
1,389,812
Long term investments
72,478
60,303
Excess cash
1,767,705
1,264,479
Stockholders' equity
4,748,396
5,597,469
Invested Capital
6,199,766
7,950,988
ROIC
16.55%
14.52%
ROCE
13.31%
12.60%
EV
Common stock shares outstanding
1,578,715
1,614,629
Price
15.00
-16.85%
18.04
-57.05%
Market cap
23,680,724
-18.70%
29,127,902
-56.19%
EV
23,812,446
30,654,679
EBITDA
1,219,471
1,305,757
EV/EBITDA
19.53
23.48
Interest
81,045
57,847
Interest/NOPBT
7.61%
4.96%